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Fifty canine mammary gland tumours (CMGT) (18 benign and 32 malig-
nant) were studied by immunohistochemical detection of active caspase-3 and Ki-
67 antigens in order to determine their association with several clinicopathological 
parameters. The percentage of caspase-3 positive cells was significantly higher in 
benign tumours as compared to their malignant counterparts (P ≤ 0.001). In the 
group of malignant tumours there was no significant association between active 
caspase-3 and the clinicopathological variables considered. The percentage of Ki-
67 positive cells was significantly higher in malignant tumours compared to the 
benign ones (P ≤ 0.001). In the group of malignant tumours, Ki-67 expression 
showed a statistically significant association with tumour size (P = 0.025), histo-
logical type (P = 0.010), mitotic grade (P ≤ 0.001), nuclear grade (P = 0.025), dif-
ferentiation grade (P = 0.004), histological grade of malignancy (P = 0.002), and 
presence of metastases in regional lymph nodes (P = 0.025). Furthermore, this 
study revealed a negative correlation between the percentages of active caspase-3 
and Ki-67 (r = –0.39; P = 0.04). Thus, our results suggest a loss of balance be-
tween cell death and cell division in CMGT.  
Key words: Apoptosis, caspase-3, Ki-67, proliferation, canine mammary 
gland tumour  
One of the best understood mechanisms of programmed cell death is apop-
tosis, which plays an essential role in the maintenance of homeostasis and devel-
opment, as well as in cellular stress response (Elmore, 2007; Roth, 2009). Apop-
tosis is an orchestrated cellular mechanism profoundly implicated in develop-
mental biology and tissue homeostasis, and it occurs under both physiological 
and pathological conditions (Kim et al., 2006). Some studies have demonstrated 
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that dysregulated apoptosis is associated with the development of cancer and 
contributes to the different steps of carcinogenesis (de Bruin and Medema, 2008). 
Apoptosis can be triggered by intrinsic and extrinsic pathways and, in mammals, 
is mediated by a family of cysteine proteases known as caspases (Degterev et al., 
2003). Once activated, caspases can cleave a wide variety of cellular targets, 
such as cytoskeletal proteins, oncoproteins, and proteins of the DNA repair sys-
tem. Particularly, active caspase-3 is responsible for the fragmentation of DNA 
(Hadjiloucas et al., 2001). The appearance of this molecule in the cytoplasm of 
apoptotic cells is an early event that precedes the development of classical apop-
totic morphological features. Thus, the immunohistochemical evaluation of active 
caspase-3 allows the detection of an early stage of apoptosis (Hadjiloucas et al., 
2001). In addition, caspase-3 is considered the main executioner of cell-death-
dependent caspase activation and an important apoptotic indicator of morpho-
logical and biochemical changes associated with apoptosis (Degterev et al., 2003). 
However, the view of apoptosis as the only form of programmed cell death, en-
tirely dependent on caspases, is now challenged by several findings. Accumulat-
ing evidence suggests that cell death can occur in a programmed pattern but in the 
complete absence, and independently, of caspase activation (Cummings et al., 
2004; Tait and Green, 2008). Alternative models of programmed cell death have 
been proposed, including autophagy, paraptosis, mitotic catastrophe, and cas-
pase-independent cell death (CICD) pathways. All of them are important safe-
guard mechanisms to protect the organism against unwanted and potentially 
harmful cells when caspase-mediated pathways fail. Moreover, they can also be 
triggered in response to cytotoxic agents and cancer (Cummings et al., 2004; Tait 
and Green, 2008; Constantinou et al., 2009). Although CICD and caspase-
dependent cell death have different enzymes involved in their cascades, they of-
ten share common characteristics, and sometimes these two pathways can be ac-
tivated simultaneously by the same stimuli (Cregan et al., 2004).  
Programmed cell death, especially apoptosis, has been extensively investi-
gated in a variety of cancers including mammary tumours (Okada and Mak, 
2004; Hanahan and Weinberg, 2011). In human breast cancer, there is no con-
sensus regarding the role of apoptosis in carcinogenesis. Some authors claim that 
high apoptotic indices are related to tumour aggressiveness. However, other re-
searchers found no relationship between the apoptotic index and the parameters 
of tumour aggressiveness. Regarding canine mammary gland tumours (CMGT), 
a few studies have been conducted to investigate the role of apoptosis in carcino-
genesis and tumour malignancy, using different antibodies (Kumaraguruparan et 
al., 2006; Yang et al., 2006). A recent study using an antibody against the active 
caspase-3 has not found a statistically significant correlation with the clinicopa-
thological parameters considered (Bongiovanni et al., 2014). 
Uncontrolled proliferation is an already known hallmark of malignancy in 
human and canine mammary tumours, and several studies have focused on this 
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topic (Labelle et al., 2004; De Matos et al., 2006; Richardsen et al., 2012; Santos 
et al., 2013). Ki-67 is a non-histone nuclear protein associated with cellular pro-
liferation and is usually detected with MIB-1 antibody. Although the precise 
function of this protein is uncertain, its tight association with the cell-cycle regu-
lation phase and its short half-life render this protein a valid marker for the as-
sessment of the growth fraction of neoplastic cells (Klopfleisch et al., 2011; In-
wald et al., 2013; Ricciardi et al., 2015). The high Ki-67 index has been posi-
tively correlated with metastasis, death from neoplasia, low disease-free survival 
rates, and low overall survival rates in both humans and dogs (Labelle et al., 
2004; De Matos et al., 2006; Richardsen et al., 2012; Santos et al., 2013). 
Anomalies in the activity of the regulatory proteins that guarantee the or-
derly progression of cells can lead to increased cell proliferation, poor mainte-
nance of chromosomal integrity, or promotion of tumour growth (Hanahan and 
Weinberg, 2011). 
As far as we know, there is only a single study on cleaved caspase-3 ex-
pression in CMGT (Bongiovanni et al., 2014), and only few studies have investi-
gated the possible relationship between apoptosis and proliferation in these tu-
mours. The goal of the present work was to elucidate the relationship between 
apoptosis and tumour proliferation in CMGT. 
 
 
Materials and methods 
Tumour specimens 
Samples from 50 CMGTs were included in the study. The material was 
fixed in 10% neutral buffered formalin and embedded in paraffin wax. Sections 
(4 μm) were stained with haematoxylin and eosin (HE). The tumours were classi-
fied according to the World Health Organization (WHO) criteria for CMGTs 
(Misdorp, 1999) and graded as described by Goldschmidt et al. (2011). Each 
sample was assessed for size (T1 < 3 cm; T2 ≥ 3 and < 5 cm; T3 ≥ 5 cm), skin 
ulceration, histological type, presence of necrosis, mitotic grade, nuclear grade, 
differentiation grade, histological grade of malignancy, and regional lymph node 
metastasis. 
Immunohistochemistry (IHC) 
The detection of caspase-3 and Ki-67 was carried out by the streptavidin–
biotin–peroxidase complex method, using the Ultra Vision Detection System kit 
(Lab Vision Corporation) according to the manufacturer’s instructions. 
For caspase-3 and Ki-67, 3-µm consecutive sections were cut and mounted 
on silane-coated slides. For caspase-3, antigen retrieval was performed by mi-
crowave treatment for 2 × 5 min at 600 W in 0.01 M citrate buffer (pH 6.0), fol-
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lowed by cooling for 20 min at room temperature. For Ki-67, antigen retrieval 
was performed by microwave treatment for 4 × 5 min at 750 W in 0.01 M citrate 
buffer (pH 6.0), followed by cooling for 20 min at room temperature. All sec-
tions were incubated with a primary monoclonal antibody specific for caspase-3 
(clone ASP 175, Cell Signaling Technology; 1:200 dilution; 24 h at 4 °C) and for 
Ki-67 (clone MIB-1, Dako, 1:50 dilution; 24 h at 4 °C). The antibody reaction 
products were ‘visualised’ with the chromogen 3,3′-diaminobenzidine tetrachlo-
ride (DAB) at 0.05% concentration with 0.01% H2O2 (30%). After final washing 
in distilled water, the sections were counterstained with haematoxylin, dehy-
drated, cleared and mounted. The primary antibody was replaced with phosphate 
buffered saline (PBS) for negative controls. Positive controls were the thymus of 
a young dog for caspase-3 and canine epidermis for Ki-67 (an internal positive 
control). 
Quantification of immunoreactivity 
The quantification of immunoreactivity was performed simultaneously by 
two observers. To evaluate caspase-3 and Ki-67 immunoreactivity, two areas 
with the most intense labelling were selected, avoiding areas of necrosis or in-
flammatory cell infiltration. In the selected areas a total of 1000 tumour cells 
were counted with the help of a microscopic grid, at high magnification. The re-
sults were expressed as a percentage of labelled cells in a total of 1000 tumour 
cells (Pathmanathan and Balleine, 2013; Bongiovanni et al., 2014). 
Statistical analysis 
The statistical software SPSS (Statistical Package for the Social Sciences) 
version 19.0 was used for statistical analysis. Analysis of variance (ANOVA) 
was used for analysing continuous variables. The Chi-square test and the Fisher’s 
exact test were used to study the categorical variables. Pearson’s correlation test 
was performed in order to verify the presence of correlation between values of 
cleaved caspase-3 and Ki-67. All values were expressed as means ± standard de-





Benign tumours (n = 18) were classified as simple adenomas (n = 5; 10%), 
complex adenomas (n = 4; 8%), and benign mixed tumours (n = 9; 18%). Malig-
nant tumours (n = 32) were diagnosed as complex carcinomas (n = 6; 12%), solid 
carcinomas (n = 6; 12%), tubulopapillary carcinomas (n = 15; 30%) and carcino-
sarcomas (n = 5; 10%).  
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Expression of caspase-3 and Ki-67 in canine mammary gland tumours 
Immunoreactivity for caspase-3 was observed in the cytoplasm of neoplas-
tic cells in a diffuse pattern. In some cases, nuclear staining was also observed 
(Fig. 1A,B). Immunostaining for Ki-67 was only observed in the nucleus in a 
granular labelling pattern associated with the nucleoli. Staining in the nucleoli 
occurred homogeneously and intensely (Fig. 1C,D). 
Differences in the percentage of caspase-3 and Ki-67 positivity  
between benign and malignant CMGT 
A statistically significant difference (P < 0.001) in the percentage of cas-
pase-3 positivity was observed in malignant tumours when compared to benign 
ones (Fig. 2). Malignant tumours showed less apoptotic cells (mean value: 0.647 ± 
0.0914%) than benign neoplasms (mean value: 9.478 ± 2.308%). The percentage 
of Ki-67 observed for malignant and benign CMGT also presented significant 
differences between the two groups (P < 0.001) with higher values recorded for 
malignant tumours (25.347 ± 2.139%) than for benign neoplasms (7.867 ± 
1.0482%) (Fig. 3). 
 
Fig. 2. Differences in caspase-3 positivity (%) between benign and malignant canine mammary 
gland tumours 
Association between the percentage of caspase-3 and Ki-67 positivity  
and clinicopathological variables in malignant CMGT 
The percentage of caspase-3 did not show any association with the clini-
copathological variables considered in the study. For the percentage of Ki-67, 
statistically significant associations were observed with tumour size (P = 0.025), 
histological type (P = 0.01), mitotic grade (P ≤ 0.001), nuclear grade (P = 0.025), 
differentiation grade (P = 0.004), histological grade of malignancy (P = 0.002), and 
lymph node metastasis (P = 0.010). Detailed information is provided in Table 1. 
P < 0.001 
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Fig. 3. Differences in Ki-67 positivity (%) between benign and malignant canine mammary gland 
tumours 
Correlation between the percentage of caspase-3 and Ki-67 positivity 
In this study, a negative and statistically significant correlation was ob-
served between the percentages of caspase-3 and Ki-67 positivity in the group of 
malignant tumours (n = 32; r = –0.39; P = 0.04), while no significant correlation 




Cell death, particularly apoptosis, is probably one of the most widely-
studied subjects in human cancers. Many tumour cells carry mutations in key 
apoptotic genes such as p53, Bcl family proteins or the genes affecting caspase 
signalling (Ryoo and Bergmann, 2012). 
However, in veterinary medicine only few data have been published about 
the implication of apoptosis in the diagnosis and/or malignancy of canine tu-
mours and, to the best of our knowledge, there is only a single study that used an 
antibody to the active form of caspase-3 in these tumours (Bongiovanni et al., 
2014). 
The present results demonstrated a statistically significant difference in the 
percentage of caspase-3 positive cells between benign and malignant tumours, 
with the malignant cases showing less apoptotic cells than benign ones. These 
findings suggest that caspase-dependent apoptotic pathways are inhibited during 
tumour progression. The percentage of active caspase-3 was not significantly as-
sociated with any clinicopathological feature, and our results are consistent with the 
findings of a study in canine osteosarcoma (Bongiovanni et al., 2012). In human 
oncology, several studies have been conducted on this topic, with contradictory 
results. Some researchers showed that high levels of apoptosis were associated 
P < 0.001 
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with the nuclear grade, the degree of differentiation, an increased risk of metasta-
sis and the loss of oestrogen receptors. The relationship between a high apoptotic 
index and a good prognosis was not substantiated (Lipponen et al., 1994). These 
inconsistencies in the results may be attributable to the simultaneous existence of 
several other factors contributing to tumour progression, such as other forms of 
programmed cell death, rate of proliferation, angiogenesis, and immune response 
of the host that happen to influence the behaviour of the tumour and its reaction 
to therapy (Hanahan and Weinberg, 2011). The lack of other studies describing 
these findings, both in human and veterinary medicine, precludes more adequate 
comparisons and justifies the need for further investigations in order to clarify 
this subject. 
Cell proliferation is a process controlled by regulatory proteins that guar-
antee the orderly progression of cells throughout the cell cycle (Madewell, 2001). 
Anomalies in the activity of these regulatory proteins can lead to increased cell 
proliferation, poor maintenance of chromosomal integrity, and promotion of tu-
mour growth (Hanahan and Weinberg, 2011). Our results demonstrated that the 
percentage of Ki-67 positive cells observed for malignant and benign CMGT 
presented significant differences between the two groups with higher values reg-
istered for malignant tumours than for benign neoplasms. These results are in 
agreement with the findings of previous studies on human breast cancer and on 
CMGT (Lipponen et al., 1994; Labelle et al., 2004; Nowak et al., 2008; Pathma-
nathan and Balleine, 2013). These findings highlight the crucial role of Ki-67 in 
tumour progression, as reported by several authors (Pena et al., 1998; Labelle et 
al., 2004; Sorenmo et al., 2011). For Ki-67 expression there was a statistically 
significant association with larger tumour size, histological type, mitotic index, 
nuclear grade, histological grade of malignancy, and the presence of lymph node 
metastasis. Similar results have already been described by other researchers for 
human and canine mammary tumours (Labelle et al., 2004; De Matos et al., 
2006; Richardsen et al., 2012; Santos et al., 2013). 
Our data also demonstrated a statistically significant negative correlation 
between active caspase-3 and Ki-67 expression in the malignant tumour group. 
The rate of tumour growth is determined by cell death and proliferation. An im-
balance between tumour cell proliferation and death is critical for the growth, 
progression and regression of the tumour (Hanahan and Weinberg, 2011). There-
fore, qualitative and quantitative changes in the death of tumour cells with prolif-
erative changes are essential and determinant in the pathogenesis of malignant 
disease and its responsiveness to therapy (Okada and Mak, 2004). 
Our study suggests a loss of balance between cell death and cell division 
in CMGT. In these tumours, the pathways implicated in cell death and prolifera-
tion were altered and tumour cells that should be detected as foreign were not 
appropriately signalled. 
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Table 1 
Relationship between caspase-3 and Ki-67 expression (%) and clinicopathological parameters in 
malignant canine mammary tumours 
Ki-67 Caspase-3 









 T1 < 3 cm 
 T2 ≥ 3 cm and < 5 cm 
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 Solid c. 


















































































































































n: number of samples; P: statistical significance; NS: not significant 
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Cell survival, proliferation, migration, metabolism, angiogenesis and 
apoptosis are mediated by a range of pivotal signalling pathways that have a 
regulatory function, such as PI3K/AKT/mTOR and Ras-Raf/MEK/ERK signal-
ling (Fruman and Rommel, 2014). Abnormal activation of these pathways, 
caused by PI3K mutation, KRAS mutation, PTEN loss, AKT1 mutation and 
other mechanisms, is possibly the most commonly activated deregulated prolif-
eration and apoptotic signalling pathway in human breast cancer (Liu et al., 
2009; Hernandez-Aya and Gonzalez-Angulo, 2011). Many studies showed that 
more than 70% of breast tumours have molecular alterations in at least one com-
ponent of these pathways (Hernandez-Aya and Gonzalez-Angulo, 2011), and our 
results suggest that in CMGT similar pathways could be involved. Although the 
deregulated cell proliferation and the suppression of apoptosis that are needed to 
support neoplastic progression can be activated simultaneously by the same 
stimuli, they might sometimes be regulated by different and independent signal 
and mutation types (Ryoo and Bergmann, 2012), which claims for additional re-
search on this topic. 
Understanding the network of apoptosis and proliferation in CMGT is 
very important as it not only gives insights into the pathogenesis of the disease, 
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